Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock News

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company's oral delivery platform, at ObesityWeek® 2025 taking place both virtually and...

SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham (“Abe”) Bassan and Vasudev Bailey, Ph.D.

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr.

Rani Therapeutics is initiated at a Buy rating, driven by major pipeline advancements and strong partnership momentum. RANI secured a $1.085 billion collaboration with Chugai Pharmaceutical, leveraging RaniPill technology to target rare and immunological disorders with oral biologics. Positive preclinical data for RT-114 (oral GLP-1/GLP-2 agonist) and an oversubscribed $60.3 million private pla...

Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partnerships, investors are rewarding progress across oncology, immunology, and drug delivery platforms.

Rani Therapeutics Holdings (NASDAQ: RANI) shocked the stock market on Friday as its shares soared 248% to close at $1.64, following a collaboration with Japan's Chugai Pharmaceutical.

Rani Therapeutics said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical , with an option to extend it to up to five drugs, potentially bringing the total deal value to $1.09 billion.